MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS Conference

Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS . NEURO-ONCOLOGY, 18 115-115.

International Collaboration

cited authors

  • Bell, Erica H; Zhang, Peixin; Fisher, Barbara J; Macdonald, David R; McElroy, Joseph P; Lesser, Glenn J; Fleming, Jessica; Chakraborty, Arup; Liu, Ziyan; Becker, Aline Paixao; Fabian, Denise; Aldape, Kenneth D; Ashby, Lynn S; Werner-Wasik, Maria; Walker, Eleanor M; Bahary, Jean-Paul; Kwok, Young; Yu, Michael; Laack, Nadia N; Schultz, Christopher J; Gray, Heidi J; Robins, H Ian; Mehta, Minesh P; Chakravarti, Arnab

authors

date/time interval

  • November 17, 2016 -

publication date

  • November 1, 2016

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • AZ, Scottsdale

Conference

  • 21st Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology

publisher

  • OXFORD UNIV PRESS INC

start page

  • 115

end page

  • 115

volume

  • 18